What's Happening

For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

For the treatment of hypertension and coronary artery disease

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity

Indicated for the control of absence (petit mal) seizures that are refractory to other drugs

A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19

Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes

Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use

Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages

Indicated for the treatment of partial-onset seizures in adults

Indicated for the treatment of schizophrenia or as maintenance monotherapy treatment of bipolar I disorder

Indicated for the treatment of schizophrenia in adults

Indicated for the acute treatment of migraine with or without aura

Indicated for the short term management of mild to moderate acute pain